Leadership Team

White_final_croppedDaniel H. White, President and CEO
Mr. White is a founder of our company and has served as our President and Chief Executive Officer and as a member of our board of directors since our inception in May 2011.  From 2008 to 2011, Mr. White served as Executive Director, Global Corporate Development, for Stiefel Laboratories, Inc., a dermatology pharmaceutical company acquired by GlaxoSmithKline in 2009.  From 2007 to 2008, he co-founded and served as President and Chief Executive Officer of Percept BioScience, Inc., a biotechnology company.  In 2003, Mr. White co-founded, and until 2007 served as Vice President of Finance and Corporate Development of Alimera Sciences, Inc., a biopharmaceutical company focused on ophthalmology.  Previously he was Head of Business Development and Licensing for CIBA Vision, a Novartis company, and Director of Licensing and Business Development for AAIPharma.  Mr. White holds an M.B.A. degree from Wake Forest University and a B.S. degree in molecular biology from Auburn University.

Andino_final_croppedRafael V. Andino, Vice President, Engineering & Manufacturing
Mr. Andino has served as our Vice President, Engineering & Manufacturing since February 2013.  Since June 2013, Mr. Andino has also served as an adjunct professor of biomedical engineering at the Georgia Institute of Technology.  From January 2009 to February 2013, he served as Director of Research and Development for Bard Medical, a division of C.R. Bard, Inc., a publicly traded company.  In 1999, Mr. Andino founded, and until 2008 served as President and Chief Executive Officer of Biofisica, Inc., a biotechnology company that developed technology to expedite wound healing and regeneration of connective tissue in humans.  Prior to founding Biofisica, from 1995 to 2005 Mr. Andino was a mechanical engineer, research and development director and senior project manager for CIBA Vision, a Novartis company.  He has also worked for the global technology companies E.I. Dupont de Nemours, General Electric and IBM.  Mr. Andino received his Bachelor’s degree in Mechanical Engineering from the Georgia Institute of Technology, a Master of Science in Biomedical Engineering from the University of Alabama at Birmingham and an M.B.A. from Mercer University.

Richard L. Beckman, MD, Chief Medical Officer
Dr. Beckman is a board certified ophthalmologist who brings 13 years of clinical practice experience and over 20 years of corporate executive and consultancy experience within the global ophthalmic industry to Clearside.
Prior to joining Clearside, Dr. Beckman managed a successful pharmaceutical and medical device industry consulting firm that served a broad range of companies. Previously, he held the position of Chief Medical Officer and General Manager of the Ocular and Novel Drug Delivery Systems business unit at Unilife Corporation. He has also held senior leadership roles with Ophthotech Pharmaceuticals, Neurotech Pharmaceuticals, Alcon Laboratories, Lux Pharmaceuticals and Becton-Dickinson. Dr. Beckman received his medical degree from the University of Michigan, and practiced as a glaucoma specialist for three years in academic practice at North Shore University Hospital-Cornell University Medical College, and for ten years in private practice following an ophthalmology residency at Henry Ford Hospital and a Glaucoma Fellowship at Harvard University.

Deignan_final_croppedCharles A. Deignan, Chief Financial Officer
Mr. Deignan has served as our Chief Financial Officer since January 2012.  From 2009 to December 2011, Mr. Deignan was Vice President of Finance and Administration for Salutria Pharmaceuticals.  Previously, from 1999 to 2009, Mr. Deignan served in a number of roles with AtheroGenics, Inc., a publicly held biopharmaceutical company, including as its Vice President of Finance and Administration.  Prior to that, he held management positions at AAIPharma, Inc., and Schering-Plough.  Mr. Deignan received his B.S. degree in Business Administration from Boston University.

Jennifer-outside_266x266Jennifer Kissner, Ph.D., Vice President, Clinical Development
Dr. Kissner was promoted to Vice President, Clinical Development in August, 2016 after having served as Clearside’s Senior Director of Development since August 2014. Dr. Kissner has 14 years of clinical development experience, 9 of which have been with entities addressing sight-threatening diseases in positions at ophthalmology companies such as Alcon Laboratories, Inc., a Novartis company and Acucela, Inc. Dr. Kissner received her Ph.D. and conducted her post-doctoral research at Emory University before spending five years at Vanderbilt University addressing infectious diseases while holding several positions of increasing responsibility in the Department of Pediatrics and developing a centralized clinical research office.

rick_266x266 Rick McElheny, Vice President, Business Development
Mr. McElheny has served as our Vice President, Business Development since November 2016. From 2011 to 2015, Mr. McElheny Founded and served as Vice President Corporate Development and Supply Chain for Vidara Therapeutics, a specialty pharmaceutical company focused on developing and marketing orphan drugs. From 2005 to 2011, he worked in various roles at Meda Pharmaceuticals including business development, market research, and supply chain management. Prior to Meda Pharmaceuticals he worked in various supply chain roles at Johnson and Johnson and Schering Plough. Mr. McElheny holds an M.B.A. degree from New York University and B.S. degrees in Environmental Resource Management and Business Management from Penn State University.

Noronha_final_croppedGlenn Noronha, Ph.D., Chief Scientific Officer
Dr. Noronha was promoted to CSO in August, 2016 after having served as Clearside’s Executive Vice President, Research and Development since August 2013.  From August 2012 to May 2013, he served as Vice President, Research and Development at Sucampo Pharma Americas, LLC, a pharmaceutical company.  From July 2011 to July 2012, Dr. Noronha was Chief Scientific Officer for JW Theriac, Inc., a pharmaceutical company focused on new drug research and development.  From 2008 to 2011, Dr. Noronha was Global Project Head for Retinal Development at Alcon Laboratories, Inc., a Novartis company.   From 2002 to 2008, Dr. Noronha held several positions at TargeGen, Inc., a pharmaceutical company, including as co-lead for its ophthalmology programs.  Previously, from 2000 to 2002, he was a research scientist and project leader for Medtronic MiniMed, Inc.  Dr. Noronha received his Ph.D. degree from Loyola University of Chicago and was a post-doctoral fellow at the University of California at Irvine.